SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Nordestgaard Børge G) "

Sökning: WFRF:(Nordestgaard Børge G)

  • Resultat 21-26 av 26
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
21.
  • Watts, Eleanor L., et al. (författare)
  • Observational and genetic associations between cardiorespiratory fitness and cancer : a UK Biobank and international consortia study
  • 2023
  • Ingår i: British Journal of Cancer. - 0007-0920 .- 1532-1827.
  • Tidskriftsartikel (refereegranskat)abstract
    • Background: The association of fitness with cancer risk is not clear.Methods: We used Cox proportional hazards models to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for risk of lung, colorectal, endometrial, breast, and prostate cancer in a subset of UK Biobank participants who completed a submaximal fitness test in 2009-12 (N = 72,572). We also investigated relationships using two-sample Mendelian randomisation (MR), odds ratios (ORs) were estimated using the inverse-variance weighted method.Results: After a median of 11 years of follow-up, 4290 cancers of interest were diagnosed. A 3.5 ml O2⋅min−1⋅kg−1 total-body mass increase in fitness (equivalent to 1 metabolic equivalent of task (MET), approximately 0.5 standard deviation (SD)) was associated with lower risks of endometrial (HR = 0.81, 95% CI: 0.73–0.89), colorectal (0.94, 0.90–0.99), and breast cancer (0.96, 0.92–0.99). In MR analyses, a 0.5 SD increase in genetically predicted O2⋅min−1⋅kg−1 fat-free mass was associated with a lower risk of breast cancer (OR = 0.92, 95% CI: 0.86–0.98). After adjusting for adiposity, both the observational and genetic associations were attenuated.Discussion: Higher fitness levels may reduce risks of endometrial, colorectal, and breast cancer, though relationships with adiposity are complex and may mediate these relationships. Increasing fitness, including via changes in body composition, may be an effective strategy for cancer prevention.
  •  
22.
  •  
23.
  • Brandão, Andreia, et al. (författare)
  • The CHEK2 Variant C.349A>G Is Associated with Prostate Cancer Risk and Carriers Share a Common Ancestor
  • 2020
  • Ingår i: Cancers. - : MDPI AG. - 2072-6694. ; 12:11
  • Tidskriftsartikel (refereegranskat)abstract
    • The identification of recurrent founder variants in cancer predisposing genes may have important implications for implementing cost-effective targeted genetic screening strategies. In this study, we evaluated the prevalence and relative risk of the CHEK2 recurrent variant c.349A>G in a series of 462 Portuguese patients with early-onset and/or familial/hereditary prostate cancer (PrCa), as well as in the large multicentre PRACTICAL case-control study comprising 55,162 prostate cancer cases and 36,147 controls. Additionally, we investigated the potential shared ancestry of the carriers by performing identity-by-descent, haplotype and age estimation analyses using high-density SNP data from 70 variant carriers belonging to 11 different populations included in the PRACTICAL consortium. The CHEK2 missense variant c.349A>G was found significantly associated with an increased risk for PrCa (OR 1.9; 95% CI: 1.1-3.2). A shared haplotype flanking the variant in all carriers was identified, strongly suggesting a common founder of European origin. Additionally, using two independent statistical algorithms, implemented by DMLE+2.3 and ESTIAGE, we were able to estimate the age of the variant between 2300 and 3125 years. By extending the haplotype analysis to 14 additional carrier families, a shared core haplotype was revealed among all carriers matching the conserved region previously identified in the high-density SNP analysis. These findings are consistent with CHEK2 c.349A>G being a founder variant associated with increased PrCa risk, suggesting its potential usefulness for cost-effective targeted genetic screening in PrCa families.
  •  
24.
  •  
25.
  • Mellby, Linda D., et al. (författare)
  • Serum biomarker signature-based liquid biopsy for diagnosis of early-stage pancreatic cancer
  • 2018
  • Ingår i: Journal of Clinical Oncology. - 0732-183X. ; 36:28, s. 2887-2894
  • Tidskriftsartikel (refereegranskat)abstract
    • Purpose Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis, with a 5-year survival of, 10% because of diffuse symptoms leading to late-stage diagnosis. That survival could increase significantly if localized tumors could be detected early. Therefore, we used multiparametric analysis of blood samples to obtain a novel biomarker signature of early-stage PDAC. The signature was derived from a large patient cohort, including patients with well-defined early-stage (I and II) PDAC. This biomarker signature was validated subsequently in an independent patient cohort. Patients and Methods The biomarker signature was derived from a case-control study, using a Scandinavian cohort, consisting of 16 patients with stage I, 132 patients with stage II, 65 patients with stage III, and 230 patients with stage IV PDAC, and 888 controls. This signature was validated subsequently in an independent case-control cohort in the United States with 15 patients with stage I, 75 patients with stage II, 15 patients with stage III, and 38 patients with stage IV PDAC, and 219 controls. An antibody microarray platform was used to identify the serum biomarker signature associated with early-stage PDAC. Results Using the Scandinavian case-control study, a biomarker signature was created, discriminating samples derived from patients with stage I and II from those from controls with a receiver operating characteristic area under the curve value of 0.96. This signature, consisting of 29 biomarkers, was then validated in an independent case-control study in the United States. The biomarker signature could discriminate patients with stage I and II PDAC from controls in this independent patient cohort with a receiver operating characteristic area under the curve value of 0.96. Conclusion This serum biomarker signature might represent a tenable approach to detecting early-stage, localized PDAC if these findings are supported by a prospective validation study.
  •  
26.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 21-26 av 26
Typ av publikation
tidskriftsartikel (23)
forskningsöversikt (3)
Typ av innehåll
refereegranskat (26)
Författare/redaktör
Nordestgaard, Børge ... (25)
Giles, Graham G (8)
Bojesen, Stig E. (7)
Southey, Melissa C. (7)
Easton, Douglas F. (7)
Chang-Claude, Jenny (6)
visa fler...
Haiman, Christopher ... (6)
Brenner, Hermann (6)
Dunning, Alison M. (6)
Tybjaerg-Hansen, Ann ... (6)
Nevanlinna, Heli (5)
Milne, Roger L. (5)
Benitez, Javier (5)
Brauch, Hiltrud (5)
Chenevix-Trench, Geo ... (5)
Cox, Angela (5)
Hamann, Ute (5)
Hopper, John L. (5)
Mannermaa, Arto (5)
Pharoah, Paul D. P. (5)
Nielsen, Sune F. (5)
Danesh, John (5)
Kosma, Veli-Matti (5)
Blomqvist, Carl (4)
Salomaa, Veikko (4)
Cybulski, Cezary (4)
Teixeira, Manuel R (4)
Neuhausen, Susan L (4)
Sattar, Naveed (4)
Borén, Jan, 1963 (4)
Severi, Gianluca (4)
Wareham, Nicholas J. (4)
Devilee, Peter (4)
Hall, Per (4)
Lissowska, Jolanta (4)
Couch, Fergus J. (4)
Schmidt, Marjanka K. (4)
Garcia-Closas, Monts ... (4)
Langenberg, Claudia (4)
Scott, Robert A (4)
Le Marchand, Loïc (4)
Baglietto, Laura (4)
Beesley, Jonathan (4)
Hovingh, G. Kees (4)
Wiklund, Olov, 1943 (4)
Bruckert, Eric (4)
Reed, Malcolm W R (4)
Chapman, M. John (4)
Olson, Janet E. (4)
Wang-Gohrke, Shan (4)
visa färre...
Lärosäte
Göteborgs universitet (8)
Umeå universitet (8)
Uppsala universitet (8)
Lunds universitet (7)
Karolinska Institutet (7)
Stockholms universitet (1)
visa fler...
Högskolan Dalarna (1)
visa färre...
Språk
Engelska (26)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (22)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy